Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Fineline Cube Jul 9, 2026
Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Fineline Cube Jul 9, 2026
Company

Sanofi’s Commitment to China: Expansion, Digital Innovation, and Local R&D

Fineline Cube May 31, 2023

Wayne Shi, president of France-based Sanofi’s (NASDAQ: SNY) Greater China business, has been discussing the...

Company Deals

XtalPi Partners with Eli Lilly for AI-Driven Drug Discovery Services

Fineline Cube May 31, 2023

Sino-US artificial intelligence (AI) firm XtalPi Inc. has been enlisted by US-giant Eli Lilly &...

Company Drug

Chia Tai Tianqing’s Biosimilar Rituximab Approved by China’s NMPA for Lymphoma Treatments

Fineline Cube May 31, 2023

China-based Chia Tai Tianqing has announced receiving a market approval from the National Medical Products...

Company Drug

Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for SHR-2106 and HRS-1893 Clinical Trials

Fineline Cube May 31, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has separately announced receiving clinical trial approvals...

Company Deals

Galvanize Therapeutics Partners with Energenx Medical for Greater China Expansion

Fineline Cube May 31, 2023

US-based Galvanize Therapeutics Inc. has revealed a licensing deal with Shanghai-based Energenx Medical Ltd, which...

Company Drug

AstraZeneca Launches Calquence in China for Mantle Cell Lymphoma Treatment

Fineline Cube May 30, 2023

UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced the official market launch of Calquence...

Company Deals

Kangtai Biological Partners with Indian Pharmaceutical Giant for 13-Valent Pneumonia Vaccine

Fineline Cube May 30, 2023

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading Chinese biopharmaceutical company, has entered...

Company Deals

Medtronic Launches AiBLE Orthopedic Ecosystem and Partners with Allinmd Orthopedics in China

Fineline Cube May 30, 2023

US-based Medtronic Inc., (NYSE: MDT) has launched AiBLE, an innovative ecological ecosystem concept for orthopedics,...

Company Deals

TYK Medicines Partners with WuXi STA for Comprehensive CMC Services

Fineline Cube May 30, 2023

Shanghai-based TYK Medicines has announced a partnership with WuXi STA, a subsidiary of WuXi AppTec...

Company Deals

Beijing’s E-Health Now Secures Tens of Millions in Series B Financing

Fineline Cube May 30, 2023

E-Health Now, a comprehensive health management platform headquartered in Beijing, has reportedly raised tens of...

Company Deals

Boyi Biotech Secures Over RMB100 Million in Series A Financing Led by JOLMO

Fineline Cube May 30, 2023

Boyi Biotech, a prominent biological microspheres developer headquartered in Changzhou, has reportedly secured more than...

Company Deals

Mindray Partners with Vazyme Biotech to Develop Automated Infection Screening Solutions

Fineline Cube May 30, 2023

China-based medical device company Mindray (SHE: 300760) has entered into a partnership with fellow Chinese...

Company Drug

Hisun Pharmaceutical’s SHP2 Inhibitor HS336 Gets NMPA Clinical Trial Approval

Fineline Cube May 30, 2023

Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267), a China-based pharmaceutical company, has announced that it...

Policy / Regulatory

Hainan Boao Lecheng Introduces 319 Overseas Drugs and Devices, Reports Significant Growth

Fineline Cube May 30, 2023

The Hainan Boao Lecheng International Medical Tourism Pilot Zone has introduced 319 clinically urgently needed...

Company

Moderna Establishes USD 100 Million Subsidiary in Shanghai to Expand mRNA Technology

Fineline Cube May 29, 2023

US-based vaccine manufacturer Moderna (NASDAQ: MRNA) has registered a new subsidiary in the Minhang district...

Drug Policy / Regulatory

Hubei Leads National Volume-Based Procurement of Patented Traditional Chinese Medicines

Fineline Cube May 29, 2023

The Healthcare Security Administration (HSA) bureau of Hubei province has released a notification outlining plans...

Company Drug

Harbour Biomed’s Porustobart Combo Shows Promise in HCC Treatment, ASCO Presentation Reveals

Fineline Cube May 29, 2023

China-based Harbour Biomed (HKG: 2142) has announced the publication of results from a Phase Ib...

Company Drug

Ascentage Pharma’s Olverembatinib Earns Breakthrough Designation for SDH-Deficient GIST

Fineline Cube May 29, 2023

The China’s Center for Drug Evaluation (CDE) has granted breakthrough therapy designation (BTD) to olverembatinib,...

Company Drug

Abbisko Therapeutics Reports Positive Phase Ib Results for ABSK021 at ASCO

Fineline Cube May 29, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) is poised to announce positive results from...

Company Drug

Shanghai Yizhong’s Paclitaxel Micelles Data to be Presented at ASCO Annual Meeting

Fineline Cube May 29, 2023

Shanghai Yizhong Pharmaceutical Co., Ltd (SHA: 688091), a China-based pharmaceutical company, has announced that clinical...

Posts pagination

1 … 547 548 549 … 693

Recent updates

  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
  • Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
  • Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
  • Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST
  • Changchun High & New Technology’s Subsidiary GenSci Secures NMPA IND Acceptance for GenSci148, First-in-Class VEGF Multi-Blocker for Retinal Vascular Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Company Drug

Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.